RVNC — Revance Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual balance sheet for Revance Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	290	437	225	341	254
Net Total Accounts Receivable
Net Total Receivables	0	1.83	3.35	11.3	27.7
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	297	450	246	375	339
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	41.3	47.1	69	67.8	90.2
Net Goodwill
Net Intangible Assets
Other Long Term Assets
Total Assets	340	720	531	582	478
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	41	61	67.3	75.7	89.2
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	115	346	463	569	630
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	225	374	68.5	12.6	-152
Total Liabilities & Shareholders' Equity	340	720	531	582	478
Total Common Shares Outstanding